Johnson & Johnson’s single-dose vaccine protects against COVID but is less effective for the South African variant

The American company Johnson & Johnson announced this Friday that the trials of its vaccine show that it offers protection against COVID-19. One of the big differences of this vaccine is that it requires a single dose, unlike for example Pfizer, Moderna and AstraZeneca.

Johnson & Johnson has reported that the vaccine is 72% effective in tests carried out in the United States, but instead the global figure drops to 66% according to the study carried out on three different continents and against multiple variants of the virus , according to theGuardian. In South Africa, for example, the figure is 57%, according to The New York Times. The South African variant is one of the most worrying mutations right now, along with the British and the Brazilian.

The company intends to request emergency clearance from the Food and Drug Administration (FDA) within a week. The level of protection achieved by Johnson & Johnson is above the minimum required by the FDA, but is below the Pfizer and Moderna vaccines already approved.


Source link